Three investors contributed to the round. The startup did not indicate how it intends to use the proceeds.

NeuroTronik is classified as an other health care company and develops medical devices to treat acute heart failure. It was incorporated in 2012.North Carolina is home to over 600 biotech companies including 350 in research and development and 110 in production and manufacturing.

In 2013, NeuroTronik closed a $13.1 million Series A to develop a device that treats heart failure with neuromodulation.

The NeuroTronik Neuromodulation System™, in development, is a novel medical technology approach to help physicians treat heart failure patients who come to the hospital because of their worsened symptoms.

Acute Heart Failure Syndrome (AHFS) is a leading reason for older-adult hospitalizations in every developed healthcare market around the world. AHFS represents a difficult clinical and economic challenge for patients, physicians, hospitals, and payers.

The company hopes to meet the need of 1.2 million patients with acute heart failure in the U.S. per year.